360 Stem Cell & Regenerative Medicine Newsletter - August 12, 2014

 weSRCH's Best of the Internet Award

360 Stem Cell & Regenerative Medicine Newsletter - August 12, 2014

Featured video from Mayo Clinic: Mayo Clinic first in U.S. testing cord blood stem cells in pediatric congenital heart disease trial
Paying Forward the Gift of Life: Jorge and Leslie Bacardi
Mayo Clinic announced the first stem cell clinical trial for pediatric congenital heart disease in the United States. The trial aims to determine how stem cells from autologous umbilical cord blood can help children with hypoplastic left heart syndrome (HLHS). It will test the safety and feasibility of delivering a personalized cell-based therapy into the heart of 10 infants affected by HLHS.
New York Governor Cuomo announces more than $14 million to recruit and educate the next generation of stem cell science researchers
In a statement released by his office, Governor Andrew M. Cuomo announced that more than $14 million in funding is available to promote and support stem cell research in New York State. Governor Cuomo stated, “Providing teachers with access to advanced learning opportunities is one of the best ways that we can help them empower today’s students to become tomorrow’s researchers. The Empire State is proud to be a leader in many health-related fields, and it is my hope this program will help more New Yorkers define the face of modern medicine for years to come.” According to the statement, hands-on stem cell research opportunities will be made available to middle- and high-school biology teachers through programs developed by not-for-profit or public colleges and universities. Teachers will spend six-to-eight weeks conducting research in a stem cell laboratory and will carry their experiences back to students in lesson plans or hands-on activities to foster interest in stem cell research. The funding is available through the New York State Stem Cell Science Program (NYSTEM) and will be invested on the recommendation of the Empire State Stem Cell Board (ESSCB). NYSTEM administers New York State’s stem cell research enterprise.
UCSF: Single-Cell analysis holds promise for stem cell and cancer research
Utilizing Fluidigm Corporation’s microfluidic technology to probe human brain development, UC San Francisco researchers have identified cells’ unique features within the developing human brain and have demonstrated that large-scale cell surveys can be done much more efficiently and cheaply than was previously thought possible. Their findings were published online in Nature Biotechnology.
BBC: Stem cells show promise in stroke recovery
“Infusing stem cells into the brain may help boost recovery after a stroke, according to a pilot study by Imperial College London. Scientists believe the cells encourage new blood vessels to grow in damaged areas of the brain. They found most patients were able to walk and look after themselves independently by the end of the trial, despite having suffered severe strokes. Larger studies are needed to evaluate whether this could be used more widely.” The study is published in Stem Cell Translational Medicine.
Washington University in St. Louis: Growing human GI cells may lead to personalized treatments
Researchers from the Washington University School of Medicine in St. Louis developed a way to grow human cells from tissue taken from patients’ gastrointestinal (GI) tract. The scientists hope the technique will lead to the development of personalized treatments for inflammatory bowel conditions. The researchers were able to produce 65 cell lines from 47 patients in as short as two weeks. A cell line consists of a group of cells with the same genetic makeup. The cell lines can aid in determining the underlying problems in the gastrointestinal tracts of individual patients and later be used to test potential treatments.
Cesca Therapeutics and Fortis Healthcare announce master collaboration agreement
According to a Cesca media release, the company has expanded its scope of services as exclusive provider of regenerative medicine to the largest private hospital in Asia. The scope of services now provide for specific regenerative medicine programs including: cord blood banking services, point of care autologous cell therapy product and services, hematopoietic stem cell therapy services (i.e. both autologous and allogeneic bone marrow transplant) and oncological cellular therapy services.
Human Longevity, Inc. and Celgene Cellular Therapeutics sign license agreement to develop and commercialize placental stem cell population, PSC-100 for multiple therapeutic applications
Human Longevity, Inc. (HLI), a genomics and cell therapy-based diagnostic and therapeutic company focused on extending the healthy, high performance human life span, announced in a company press release that it has signed an agreement with Celgene to license, develop, and co-promote Celgene's proprietary placental cell population, PSC-100. HLI has the option to explore a variety of applications for this unique cell population, including for sarcopenia, a condition associated with aging characterized by degenerative loss of skeletal muscle mass, quality, and strength. Celgene also made an equity investment in HLI.
Houston Chronicle: Doris Taylor’s iconoclastic work gets to the heart of matter — stem cells
This is an excellent profile of the pioneering scientist, Doris Taylor, Ph.D. She is the director of regenerative medicine research since 2012 at the Texas Heart Institute of CHI St. Luke’s Hospital, is in charge of this heart and others. Her ambition is to introduce human stem cells into the scaffolding and grow a human heart that will beat in a human body. Editor’s note: Dr. Taylor is one of the featured speakers at the upcoming World Stem Cell Summit in San Antonio, December 3-5.
National Institutes of Health and Mesoblast enter into agreement for 120-patient trial in end-stage heart failure
According to a Mesoblast media release, the company signed an agreement with the United States National Institutes of Health's (NIH) National Heart, Lung and Blood Institute to collaborate on a trial using Mesoblast's proprietary adult stem cell therapy to treat patients with advanced heart failure requiring an implantable left ventricular assist device (LVAD) to maintain circulatory support. The National Institute of Neurological Disorders and Stroke, part of the NIH, and the Canadian Institutes for Health Research are also supporting this trial. The key objectives of using Mesoblast's Mesenchymal Precursor Cells (MPCs) in end-stage heart failure patients are to improve heart muscle function sufficiently to reduce the need for LVAD support, and to reduce the long-term complications of LVAD implantation which result in recurrent hospitalizations.
HemoGenix announces a major advancement to promote best practices in umbilical cord blood testing and patient transplant outcomes
In a HemoGenix media release, the company announced that results from its HALO family of cell therapy (CT) assays, which measure stem cell quality and potency of umbilical cord blood (UCB) units prior to transplantation, can now be uploaded to the National Marrow Donor Program (NMDP) EmTrax UCB database. The database is used by stem cell transplantation centers to search for compatible cord blood units stored in public cord blood banks for patients requiring a stem cell transplant. HemoGenix maintains that the assays can promote “best practice criteria testing” and that “inclusion of this stem cell data into the EmTrax database can provide the transplant physician with valuable, additional information regarding the ability and potential of the UCB stem cells to engraft prior to the transplantation procedure.”
The Newport Daily News: Keys to a cure- artist was commissioned to create artwork to advance the mission of regenerative medicine and stem cell research
Can a talented artist capture the wonder and hope of regenerative medicine? Read the interesting journey of artist Kelly Milukis, who has created an astounding collection of photographs, sculpture and paintings. “Visually tell the story of how the body has the ability to heal itself,” she said of the commission in 2010 from the Regenerative Medicine Foundation in Winston-Salem, N.C. “They gave me three words: keys, locks and mysteries.”

360 Newsletter Editor

Bernard Siegel
Executive Director
Genetics Policy Institute

Stem Cells and the Transformative Power of Hope-a TEDx talk by Bernard Siegel, Editor of 360 Newsletter
Domain: Medical
Category: Biology

Recent Newsletters

12 March, 2019
10 October, 2018
15 February, 2018